OncoSec Medical Inc (ONCSQ)

[guti]

The following is actually from an abstract titled "Targeting tumor-infiltrating macrophages to combat cancer" which you can read to better answer your question.

The rationale for the scientific foundation is stated as follow:

"Certain breast cancers produce CSF-1, which promote macrophage infiltration and M2 differentiation. High Th2 CD4+ T cells with low CD8+ T cells results in a protumoral environment with increased metastatic risk. Interactions between M2 macrophages and MDSCs lead to high levels of IL-10 and low levels of IL-12, further reinforcing the M2 phenotype and increasing levels of Th2-type CD4+ T cells. These CD4+ T cells produce IL-4, which also polarizes macrophages toward M2, creating a feedback loop. Meanwhile, CD8+ T cells are suppressed, resulting in an overall immune-permissive environment for tumor growth and spread."

This is exactly what Dr. Pierce has stated that can be possible with ImmunoPulse of IL-12, and it has been proven with both the MCC study and the Melanoma study by the increase of TIL's.